AEGiS-IRIN: Concerns Over HIV Treatment of Soldiers

Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.

Concerns Over HIV Treatment of Soldiers

UN Integrated Regional Information Networks - October 5, 2001

Director General of Tanzania's National Institute for Medical Research (NIMR), Andrew Kitua, has the institute received a request for permission for testing of an alleged new HIV/Aids treatment that South African researchers are conducting on Tanzanian soldiers, but that the trials had not yet been approved, the South African 'Mail and Guardian' newspaper reported on Friday, 5 October.

Neither did Kitua know of any approval for use of the coal-based substance, oxihumate-K, being used in the research on HIV-positive soldiers at Lugalo military hospital. "We [the NIMR] are in the process of investigating what is being done, and what the status is of their trials and why regulations were not followed," the report quoted him as saying.

Lugalo military hospital was the same facility where tests were recently carried out on the discredited Aids drug Virodene, the 'Mail and Guardian' reported. It quoted Kitua as saying that an application to test Virodene, whose backers were expelled from Tanzania last month, was turned down. Tanzania was now trying to clarify if there was a link between the two groups of researchers, he added.

Enerkom, an affiliate of the South African government's oil agency, the Central Energy Fund (CEF), was conducting the Tanzanian trials in conjunction with the Pretoria University academics and with the backing of the Department of Mineral and Energy Affairs, the report stated. It quoted Professor Connie Medlen, the Pretoria University immunologist handling the research, as saying that the Tanzanian army had invited Enerkom and Pretoria University to do the trials, which are due to continue for another six months. Scientists had pointed out that by Enerkom claiming oxihumate-K could boost the human immune system, it was implying the substance was a drug, the 'Mail and Guardian' reported. Neither South Africa's Health Department nor Medicines Control Council (MCC) had ever authorised Enerkom to do this, or to conduct trials on HIV-positive patients, it added.

011005
IR011008

Copyright © 2001 - Integrated Regional Information Networks (IRIN). Reproduction of this article (other than one copy for personal reference) must be cleared through the Integrated Regional Information Network. .

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980 – 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .